Johnson & Johnson Yönetim

Yönetim kriter kontrolleri 2/4

Johnson & Johnson CEO'su Joaquin Duato, Jan2022 tarihinde atandı, in görev süresi 2.92 yıldır. in toplam yıllık tazminatı $ 28.40M olup, şirket hissesi ve opsiyonları dahil olmak üzere 5.6% maaş ve 94.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.015% ine doğrudan sahiptir ve bu hisseler $ 56.47M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5 yıl ve 5 yıldır.

Anahtar bilgiler

Joaquin Duato

İcra Kurulu Başkanı

US$28.4m

Toplam tazminat

CEO maaş yüzdesi	5.6%
CEO görev süresi	2.9yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	5yrs
Yönetim Kurulu ortalama görev süresi	5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Joaquin Duato'un ücretlendirmesi Johnson & Johnson'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 29 2024	n/a	n/a	US$15b
Jun 30 2024	n/a	n/a	US$16b
Mar 31 2024	n/a	n/a	US$17b
Dec 31 2023	US$28m	US$2m	US$13b
Oct 01 2023	n/a	n/a	US$12b
Jul 02 2023	n/a	n/a	US$12b
Apr 02 2023	n/a	n/a	US$11b
Jan 01 2023	US$13m	US$1m	US$16b
Oct 02 2022	n/a	n/a	US$18b
Jul 03 2022	n/a	n/a	US$17b
Apr 03 2022	n/a	n/a	US$20b
Jan 02 2022	US$14m	US$1m	US$18b
Oct 03 2021	n/a	n/a	US$18b
Jul 04 2021	n/a	n/a	US$18b
Apr 04 2021	n/a	n/a	US$15b
Jan 03 2021	n/a	n/a	US$15b
Sep 27 2020	n/a	n/a	US$17b
Jun 28 2020	n/a	n/a	US$15b
Mar 29 2020	n/a	n/a	US$17b
Dec 29 2019	US$13m	US$970k	US$15b
Sep 29 2019	n/a	n/a	US$14b
Jun 30 2019	n/a	n/a	US$16b
Mar 31 2019	n/a	n/a	US$15b
Dec 30 2018	US$9m	US$934k	US$15b
Sep 30 2018	n/a	n/a	US$2b
Jul 01 2018	n/a	n/a	US$1b
Apr 01 2018	n/a	n/a	US$1b
Dec 31 2017	US$19m	US$897k	US$1b

Tazminat ve Piyasa: Joaquin 'nin toplam tazminatı ($USD 28.40M ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.75M ).

Tazminat ve Kazançlar: Joaquin 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Joaquin Duato (61 yo)

2.9yrs

Görev süresi

US$28,397,240

Tazminat

Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joaquin Duato	CEO & Chairman	2.9yrs	US$28.40m	0.015% $ 56.5m
Joseph Wolk	Executive VP & CFO	6.4yrs	US$13.91m	0.0029% $ 11.0m
Peter Fasolo	Executive VP & Chief Human Resources Officer	8.7yrs	US$7.50m	0.0047% $ 17.4m
Jennifer Taubert	Executive VP & Worldwide Chairman of Innovative Medicine	12.9yrs	US$11.00m	0.0064% $ 24.0m
John Reed	Executive Vice President of Innovative Medicine	1.7yrs	US$20.65m	0.00061% $ 2.3m
Robert Decker	Controller & Chief Accounting Officer	5yrs	Veri yok	0.00082% $ 3.1m
James Swanson	Executive VP & Chief Information Officer	5.1yrs	Veri yok	0.00061% $ 2.3m
Jessica Moore	Vice President of Investor Relations	3.1yrs	Veri yok	Veri yok
Dirk Brinckman	Chief Compliance Officer	no data	Veri yok	Veri yok
Elizabeth Forminard	Executive VP & Chief Legal Officer	2.2yrs	Veri yok	0.00035% $ 1.3m
Guy Lebeau	Group Chairman of MD&D Business - EMEA	no data	Veri yok	Veri yok
Kathryn Wengel	Executive VP and Chief Technical Operations & Risk Officer	6.4yrs	Veri yok	0.0034% $ 12.8m

5.0yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: 0R34 'un yönetim ekibi deneyimli ve deneyimlidir ( 5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joaquin Duato	CEO & Chairman	2.9yrs	US$28.40m	0.015% $ 56.5m
Anne Mulcahy	Independent Director	15.9yrs	US$410.00k	0.00034% $ 1.3m
Hubert Joly	Independent Director	5yrs	US$320.00k	0.00021% $ 783.7k
Marillyn Hewson	Lead Independent Director	5.7yrs	US$360.00k	0.00012% $ 447.8k
Paula Johnson	Independent Director	1.8yrs	US$352.97k	0.000010% $ 37.3k
Mark McClellan	Independent Director	11.2yrs	US$320.00k	0% $ 0
Mary Beckerle	Independent Director	9.5yrs	US$355.00k	0% $ 0
Darius Adamczyk	Independent Director	2.8yrs	US$340.00k	0.000040% $ 149.3k
Jennifer Doudna	Independent Director	6.7yrs	US$320.00k	0% $ 0
Eugene Woods	Independent Director	1.1yrs	US$89.15k	Veri yok
Mark Weinberger	Independent Director	5yrs	US$340.00k	0% $ 0
Nadja West	Independent Director	4yrs	US$340.00k	0% $ 0

5.0yrs

Ortalama Görev Süresi

62.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0R34 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5 yıldır).

Johnson & Johnson Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Johnson & Johnson Announces Executive Changes

Recent updates

Johnson & Johnson Seeks U.S. FDA Approval for First Pediatric Indications for TREMFYA (Guselkumab)

Johnson & Johnson Seeks U.S. FDA Approval for Subcutaneous Induction Regimen of Tremfya (Guselkumab) inulcerative Colitis, A First for an IL-23 Inhibitor

Upcoming dividend of US$1.24 per share

Johnson & Johnson Announces Results from Additional Analyses of the Phase 2 DAHLIA Study Highlighting Improvement in Key Measures of Disease Activity and IgG Reduction

Johnson & Johnson Announces U.S. Food and Drug Administration Grants Nipocalimab Breakthrough Therapy Designation for the Treatment of Adults Living with Moderate-To-Severe Sjogren's Disease

Johnson & Johnson Submits Applications in the U.S. and EU Seek Approval of DARZALEX FASPRO® as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma

Johnson & Johnson Announces Results from Phase 3 GRAVITI Study of Tremfya

Johnson & Johnson Highlights Innovative Neuropsychiatry Portfolio and Pipeline at Psych Congress

Johnson & Johnson Announces New Spectrem Study Findings Reveal Tremfya (Guselkumab) Effectively Clears Overlooked and Undertreated Plaque Psoriasis

Third quarter dividend of US$1.24 announced

Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson

Third quarter 2024 earnings released: EPS: US$1.11 (vs US$1.71 in 3Q 2023)

Johnson & Johnson Announces Positive Results from the Phase 2/3 Vibrance-MG Study of Nipocalimab

Johnson & Johnson Announces Tremfya Data in Both Crohn's Disease and Ulcerative Colitis

Johnson & Johnson Announces the Results of A Landmark Real-World, Head-To-Head Study Showing That Erleada (Apalutamide)

Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned

Johnson & Johnson Announces Data from Three Studies Highlighting Clinical Efficacy of Darzalex® (Daratumumab) and Darzalex Faspro in Maintenance Regimens

Johnson & Johnson Announces Interim Data from the Ongoing Phase 2 Sunrise-4 Study Showing Neoadjuvant Treatment with Investigational Tar-200 Plus Cetrelimab

Johnson & Johnson Announces Updated Results from the Phase 3 Mariposa-2 Study Which Showed Rybrevant (Amivantamab-Vmjw)

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025

Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis

Johnson & Johnson Announces Executive Changes

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş